Medicine and Dentistry
Diseases
100%
Congestive Heart Failure
94%
Percutaneous Aortic Valve Replacement
87%
Multiple Myeloma
85%
Symptomatic Treatment
68%
Aortic Stenosis
61%
Systematic Review
60%
Quality of Life
56%
Cardiology
55%
Meta-Analysis
52%
Neoplasm
51%
Malignant Neoplasm
51%
Prevalence
46%
Diagnosis
43%
Adverse Event
38%
Cardiovascular System
36%
Chemotherapy
34%
Percutaneous Coronary Intervention
33%
ST Segment Elevation Myocardial Infarction
33%
Infection
33%
COVID-19
32%
Chronic Total Occlusion
32%
Cardiovascular Disease
31%
Implantable Automatic Defibrillator
30%
Apoplexy
30%
Overall Survival
30%
Cardiovascular Risk
28%
Immunotherapy
28%
Oncology
28%
Biological Marker
28%
Pleura Mesothelioma
28%
Mitral Insufficiency
27%
Echocardiography
27%
Acute Coronary Syndrome
26%
Lung Cancer
26%
Odds Ratio
26%
Azacitidine
26%
Rituximab
26%
Defibrillator
25%
Advanced Cancer
25%
Coronary Artery Disease
24%
Transplantation
24%
Valvular Heart Disease
24%
Computer Assisted Tomography
23%
Hypervolemia
23%
Drug Therapy
23%
Hazard Ratio
23%
Retrospective Study
22%
Brain Natriuretic Peptide
22%
Outpatient
22%
Cancer Treatment
21%
Prospective Cohort Study
20%
Mesothelioma
20%
Biliary Tract Cancer
19%
Idiopathic Pulmonary Fibrosis
19%
Heart Amyloidosis
19%
Hospital Mortality
19%
Targeted Therapy
19%
Heart Left Ventricle Ejection Fraction
19%
Magnetic Resonance Imaging
18%
Personalized Medicine
18%
Maintenance Therapy
18%
Patient Referral
18%
Acute Myeloid Leukemia
18%
Non Small Cell Lung Cancer
18%
Cardiac Resynchronization Therapy
18%
Bleeding
18%
Aortic Valve Replacement
18%
Ejection Fraction
17%
Cardiac Magnetic Resonance Imaging
17%
Tricuspid Insufficiency
17%
Randomized Controlled Trial
17%
Inflammatory Bowel Disease
17%
Clinical Trial
17%
In Vitro
16%
Acute Heart Infarction
16%
Primary Percutaneous Coronary Intervention
16%
Pulmonary Artery
16%
Revascularization
15%
Immunity
15%
Heart Surgery
15%
Immune Checkpoint Inhibitor
15%
Pulmonary Hypertension
15%
Endoscopic Retrograde Cholangiopancreatography
15%
Retrospective Cohort Study
15%
Amino Terminal Sequence
15%
Hemodynamic
14%
Health Care Cost
14%
Nephropathy
14%
Thromboembolism
14%
Liver Cirrhosis
14%
Reperfusion Therapy
14%
Dyspnea
14%
Aortic Valve
14%
Disease Exacerbation
14%
Radiation Therapy
14%
All Cause Mortality
14%
Anticoagulation
14%
Thorax Pain
14%
Colorectal Carcinoma
14%
Pharmacology, Toxicology and Pharmaceutical Science
Multiple Myeloma
39%
Congestive Heart Failure
35%
Prevalence
33%
Disease
31%
Pharmacokinetics
22%
Peritoneal Dialysis Fluid
21%
Adverse Event
21%
Cohort Study
20%
ST Segment Elevation Myocardial Infarction
20%
Malignant Neoplasm
19%
Peritoneal Dialysis Fluid
19%
Retrospective Study
19%
Meropenem
19%
Chronic Total Occlusion
19%
Immune Checkpoint Inhibitor
17%
Placebo
17%
Biological Marker
16%
Hypervolemia
16%
Infection
15%
Non Small Cell Lung Cancer
15%
Prospective Cohort Study
14%
Remission
14%
Virus RNA
13%
Acute Kidney Failure
13%
Aortic Stenosis
13%
Linezolid
13%
Acute Coronary Syndrome
13%
Ciprofloxacin
13%
Heart Amyloidosis
13%
Chronic Lymphatic Leukemia
13%
Rituximab
13%
Fosfomycin
13%
Selinexor
13%
Low Density Lipoprotein Cholesterol
13%
Pulmonary Hypertension
13%
Inflammatory Bowel Disease
13%
Nonalcoholic Fatty Liver
13%
Hepatitis C Virus
13%
Cerebrovascular Accident
11%
Opiate
11%
Chemotherapy
11%
Osimertinib
10%
Empagliflozin
10%
Hospital Mortality
9%
Clinical Study
9%
Epidermal Growth Factor Receptor
9%
Viral Clearance
9%
Neoplasm
9%
Dialysis Fluid
9%
Cause of Death
9%
Progression Free Survival
8%
Antibiotics
8%
Cardiovascular Disease
8%
Immunotherapy
8%
Pancreatitis
8%
Disease Severity
8%
Chronic Thromboembolic Pulmonary Hypertension
8%
Programmed Death 1 Ligand 1
8%
Peripheral Occlusive Artery Disease
7%
Prospective Study
7%
Antiinfective Agent
7%
Coronary Artery Disease
7%
B Cell Maturation Antigen
7%
Advanced Cancer
7%
Acute Heart Infarction
7%
Liver Disease
7%
Sodium Glucose Cotransporter 2 Inhibitor
7%
Heart Injury
7%
Membrane Metalloendopeptidase
7%
Hypertensive Factor
7%
SARS Coronavirus
7%
Dexamethasone
7%
Cardiogenic Shock
7%
Glutamine
6%
Darolutamide
6%
Rosuvastatin
6%
Atorvastatin
6%
Daptomycin
6%
Dysglycemia
6%
Adenocarcinoma
6%
Proton Pump Inhibitor
6%
Pibrentasvir
6%
Prosthetic Valve Dysfunction
6%
Reducing Agent
6%
Glecaprevir
6%
Azacitidine
6%
Device Infection
6%
Metastatic Colorectal Cancer
6%
Ampicillin
6%
Enterococcus faecalis
6%
Microdosing
6%
Thrombus
6%
Lorlatinib
6%
Anaplastic Lymphoma Kinase
6%
Skin Cancer
6%
Immunoglobulin M
6%
Drug Action
6%
Malignant Pleura Effusion
6%
Lipegfilgrastim
6%
Hemolytic Anemia
6%